科学家开发了一种实验性间皮瘤药物RSO-021，其创新机制是利用天然抗生素硫链霉素禁用肿瘤细胞的抗氧化防御酶PRX3，从而杀死癌细胞。1这一策略通过改变癌症防卫机制，使其成为治疗的突破口。
在由RS Oncology赞助的一期临床试验中，该药物展现出显著疗效。1试验在2022年至2023年间于英国进行，由英国MHRA监督。1研究结果显示，RSO-021在67%的患者中成功控制了病情进展，15名患者的总生存期优于现有疗法，平均无进展生存期达4.2个月。1该药物通过导管直接进入胸部，这一给药方式具有实际应用优势，因为约90%的间皮瘤患者已植入导管。1
二期临床试验已完成，相关结果预计将在今年全球肿瘤学会议上发布。1该药物策略还可能对其他癌症类型的治疗产生应用前景。1
Scientists have developed an experimental mesothelioma treatment called RSO-021 that disables a key antioxidant enzyme in cancer cells, essentially weaponizing the tumor's own protective mechanisms against itself. 1 The drug works by targeting PRX3, an enzyme that shields cancer cells from oxidative stress, using a natural antibiotic called thiostrepton to accomplish this. 1
In a Phase 1 clinical trial sponsored by RS Oncology and conducted in the United Kingdom between 2022 and 2023 under oversight by the British MHRA, RSO-021 demonstrated promising results. 1 The drug controlled disease progression in 67% of patients, and among 15 trial participants, overall survival outcomes were superior to existing therapies. 1 The average progression-free survival period reached 4.2 months. 1 The medication is delivered directly into the chest via a catheter, a route available to approximately 90% of mesothelioma patients who have already had catheters implanted. 1
Researchers characterize the finding as a potential "game changer" in cancer treatment. 1 A Phase 2 clinical trial has already been completed, with results expected to be presented at a global oncology conference later this year. 1 This therapeutic strategy may also hold promise for treating other cancer types. 1
评论
还没有评论，欢迎留下第一条。